Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients
NCT05728125 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-06-12
Summary
Historically, clinical study participation has been biased toward certain demographics. However, there is a shortage of studies that delve into the underlying factors that influence patient participation, both positively and negatively.
Several people will be invited to enroll in this study so that it may collect a variety of data about glioblastoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.
The data collected from this study will be analyzed and used to improve the experiences of future glioblastoma patients who are recruited for medical trials.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-31
- Primary Completion
- 2025-03-31
- Completion
- 2026-03-31
More Related Trials
-
Neurocognitive Decline in Patients With Brain Metastases
NCT03508752 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
NCT01268566 ·Status: COMPLETED ·Phase: PHASE2
-
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
NCT00253669 ·Status: COMPLETED
-
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00085254 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
NCT03632135 ·Status: COMPLETED ·Phase: PHASE3
-
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
NCT06319027 ·Status: RECRUITING ·Phase: PHASE2
-
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
NCT03770468 ·Status: COMPLETED
-
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
NCT00730613 ·Status: COMPLETED ·Phase: PHASE1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
NCT03739411 ·Status: RECRUITING ·Phase: PHASE1
-
Biological Therapy in Treating Patients With Glioblastoma Multiforme
NCT00003185 ·Status: COMPLETED ·Phase: PHASE2
-
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
NCT01782976 ·Status: WITHDRAWN ·Phase: PHASE2
-
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
NCT00979862 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
NCT06855628 ·Status: SUSPENDED ·Phase: PHASE2
-
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
NCT00255671 ·Status: COMPLETED
-
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
NCT01062425 ·Status: COMPLETED ·Phase: PHASE2
-
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00053183 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
NCT01044225 ·Status: TERMINATED ·Phase: PHASE2
-
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
NCT00897663 ·Status: COMPLETED
-
Disease Progression and Treatment-induced Alterations in Glioblastoma
NCT02152748 ·Status: UNKNOWN
-
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT00662506 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
NCT05737212 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
NCT00704808 ·Status: COMPLETED
-
Cilengitide Imaging Trial in Glioblastoma
NCT01558687 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
NCT07120984 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT02709226 ·Status: COMPLETED ·Phase: PHASE1